1. Home
  2. PHVS vs DCO Comparison

PHVS vs DCO Comparison

Compare PHVS & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • DCO
  • Stock Information
  • Founded
  • PHVS 2015
  • DCO 1849
  • Country
  • PHVS Switzerland
  • DCO United States
  • Employees
  • PHVS N/A
  • DCO N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • DCO Military/Government/Technical
  • Sector
  • PHVS Health Care
  • DCO Industrials
  • Exchange
  • PHVS Nasdaq
  • DCO Nasdaq
  • Market Cap
  • PHVS 1.6B
  • DCO 1.4B
  • IPO Year
  • PHVS 2021
  • DCO N/A
  • Fundamental
  • Price
  • PHVS $22.08
  • DCO $93.42
  • Analyst Decision
  • PHVS Buy
  • DCO Strong Buy
  • Analyst Count
  • PHVS 6
  • DCO 4
  • Target Price
  • PHVS $36.50
  • DCO $119.75
  • AVG Volume (30 Days)
  • PHVS 217.1K
  • DCO 152.7K
  • Earning Date
  • PHVS 11-12-2025
  • DCO 11-06-2025
  • Dividend Yield
  • PHVS N/A
  • DCO N/A
  • EPS Growth
  • PHVS N/A
  • DCO 73.00
  • EPS
  • PHVS N/A
  • DCO 2.65
  • Revenue
  • PHVS N/A
  • DCO $795,078,000.00
  • Revenue This Year
  • PHVS N/A
  • DCO $6.20
  • Revenue Next Year
  • PHVS N/A
  • DCO $8.02
  • P/E Ratio
  • PHVS N/A
  • DCO $35.11
  • Revenue Growth
  • PHVS N/A
  • DCO 2.42
  • 52 Week Low
  • PHVS $11.51
  • DCO $51.76
  • 52 Week High
  • PHVS $26.33
  • DCO $101.47
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 49.23
  • DCO 47.19
  • Support Level
  • PHVS $22.38
  • DCO $89.88
  • Resistance Level
  • PHVS $23.64
  • DCO $101.47
  • Average True Range (ATR)
  • PHVS 1.28
  • DCO 3.94
  • MACD
  • PHVS 0.04
  • DCO -0.14
  • Stochastic Oscillator
  • PHVS 61.27
  • DCO 36.77

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About DCO Ducommun Incorporated

Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.

Share on Social Networks: